\[KJ-TFC-005\] Phase 3 Study, Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
Male or female adults aged ≥19 years at the time of informed consent.
Diagnosis of primary open-angle glaucoma or ocular hypertension.
history of or current use of triple therapy, or
history of or current use of dual therapy (dorzolamide and a topical beta-blocker), or
Central visual field defect with mean deviation (MD) ≤ -25 dB on visual field testing.
Chronic, recurrent, or severe inflammatory ocular disease (e.g., scleritis, uveitis, or herpetic keratitis).
Best-corrected visual acuity (BCVA) < 0.25 (Han Chun Suk visual acuity chart) at both screening and randomization visits.
Any condition that prevents reliable intraocular pressure (IOP) measurement.